|
Real-time Estimate
Cboe BZX
19:33:53 03/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 100.20 USD | +0.37% |
|
+0.48% | +26.89% |
| 08-20 | Mirum Pharmaceuticals Insider Sold Shares Worth $4,000,000, According to a Recent SEC Filing | MT |
| 08-19 | US FDA approves Regeneron's rare bone disorder drug | RE |
| Market Cap | 6.48B 5.59B 5.27B 4.8B 8.97B 612B 9.04B 62.37B 24.2B 313B 24.34B 23.81B 1,028B | P/E 2026 * |
-6.6x | P/E 2027 * | -124x |
|---|---|---|---|---|---|
| Enterprise Value | 6.66B 5.75B 5.41B 4.93B 9.22B 629B 9.29B 64.11B 24.88B 322B 25.02B 24.47B 1,057B | EV / Sales 2026 * |
9.57x | EV / Sales 2027 * | 8.04x |
| Free-Float |
98.34% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MIRM | Delayed | |
CBOE
| MIRM | Real-time | |
|
Tradegate
| 08D | Real-time | |
|
Boerse Muenchen
| 08D | Real-time | |
|
Deutsche Boerse AG
| 08D | Delayed | |
|
Börse Stuttgart
| 08D | Delayed | |
|
Xetra
| 08D | Delayed |
Last Transcript : Mirum Pharmaceuticals, Inc.
| 1 day | +0.49% | ||
| 1 week | +0.48% | ||
| Current month | +2.22% | ||
| 1 month | -4.17% | ||
| 3 months | +9.14% | ||
| 6 months | +14.16% | ||
| Current year | +26.89% |
| 1 week | 95.6 |  | 101.73 |
| 1 month | 88.88 | | 107 |
| Current year | 73.82 | | 130 |
| 1 year | 63.23 | | 130 |
| 3 years | 23.14 | | 130 |
| 5 years | 12.82 | | 130 |
| 10 years | 6.51 | | 130 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 47 | 21/03/2019 | |
Eric Bjerkholt
DFI | Director of Finance/CFO | 66 | 11/09/2023 |
Peter Radovich
PSD | President | 48 | 16/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Grey
CHM | Chairman | 73 | 21/03/2019 |
Patrick Heron
BRD | Director/Board Member | 55 | 07/11/2018 |
| Director/Board Member | 47 | 01/11/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 18/08/26 | Exercice | Controller/Auditor | 120,000 | 0.1968% | ||
| 11/08/26 | Sell | Chief Financial Officer | -6,001 | 0.0098% | ||
| 10/08/26 | Exercice | Founder | 60,000 | 0.0984% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.37% | +0.48% | +34.34% | +262.89% | 6.48B | |
| -0.54% | -1.82% | +56.50% | +106.87% | 1,034B | |
| +1.13% | +4.75% | +56.40% | +73.26% | 663B | |
| -0.28% | +1.03% | +23.10% | +78.51% | 462B | |
| +3.31% | -1.73% | +32.73% | +38.83% | 344B | |
| +0.34% | +5.65% | +27.75% | +47.91% | 307B | |
| +1.27% | +0.33% | -0.46% | +13.70% | 251B | |
| -0.05% | +1.33% | +55.99% | +74.32% | 239B | |
| -0.03% | +2.13% | -17.30% | -53.99% | 207B | |
| +0.37% | +0.80% | +32.80% | +99.64% | 186B | |
| Average | +0.61% | -0.49% | +30.19% | +74.19% | 369.99B | |
| Weighted average by Cap. | +0.47% | -0.83% | +38.46% | +68.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 697M 601M 566M 516M 964M 65.8B 971M 6.7B 2.6B 33.64B 2.62B 2.56B 111B | 816M 704M 663M 604M 1.13B 77.08B 1.14B 7.85B 3.05B 39.41B 3.06B 3B 129B |
| Net income | -933M -805M -758M -691M -1.29B -88.14B -1.3B -8.98B -3.48B -45.06B -3.5B -3.43B -148B | -32.99M -28.46M -26.81M -24.43M -45.66M -3.12B -46M -317M -123M -1.59B -124M -121M -5.23B |
| Net Debt | 181M 156M 147M 134M 250M 17.09B 252M 1.74B 676M 8.74B 679M 665M 28.71B | 74.95M 64.66M 60.91M 55.5M 104M 7.08B 105M 721M 280M 3.62B 281M 275M 11.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/09/26 | $100.23 | +0.40% | 66,232 |
| 02/09/26 | $99.83 | +1.52% | 495,626 |
| 01/09/26 | $98.34 | +0.30% | 398,380 |
| 31/08/26 | $98.05 | +0.61% | 419,812 |
| 28/08/26 | $97.46 | -2.30% | 426,509 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MIRM Stock
Select your edition
All financial news and data tailored to specific country editions
